Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysis.
Inna ShaforostovaSimon CallGeorg EversChristian ReichertsLinus AngenendtMatthias StelljesWolfgang E BerdelAlexander PohlmannJan-Henrik MikeschFrank RosenbauerGeorg LenzChristoph SchliemannKlaus WethmarPublished in: EJHaem (2023)
Flow cytometry-based immunophenotyping is a mainstay of diagnostics in acute myeloid leukaemia (AML). Aberrant CD56 and T-cell antigen expression is observed in a fraction subset of AML cases, but the clinical relevance remains incompletely understood. Here, we retrospectively investigated the association of CD56 and T-cell marker expression with disease-specific characteristics and outcome of 324 AML patients who received intensive induction therapy at our centre between 2011 and 2019. We found that CD2 expression was associated with abnormal non-complex karyotype, NPM1 wild-type status and TP53 mutation. CD2 also correlated with a lower complete remission (CR) rate (47.8% vs. 71.6%, p = 0.03). CyTdT and CD2 were associated with inferior 3-year event-free-survival (EFS) (5.3% vs. 33.5%, p = 0.003 and 17.4% vs. 33.1%, p = 0.02, respectively). CyTdT expression was also correlated with inferior relapse-free survival (27.3% vs. 48.8%, p = 0.04). In multivariable analyses CD2 positivity was an independent adverse factor for EFS (HR 1.72, p = 0.03). These results indicate a biological relevance of aberrant T-cell marker expression in AML and provide a rationale to further characterise the molecular origin in T-lineage-associated AML.
Keyphrases
- acute myeloid leukemia
- poor prognosis
- free survival
- flow cytometry
- binding protein
- nk cells
- clinical trial
- long non coding rna
- dendritic cells
- stem cells
- liver failure
- intensive care unit
- immune response
- emergency department
- wild type
- acute lymphoblastic leukemia
- mesenchymal stem cells
- aortic dissection
- rheumatoid arthritis
- mass spectrometry
- cell therapy
- cell fate